Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

Sponsor

Aegera Therapeutics (Industry)

Overall Status

Completed

CT.gov ID

NCT00891683

Collaborator

(none)

128

Enrollment

Locations

Arms

11.1

Duration (Months)

6.4

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Two Phase 1 studies have been conducted with AEG33773 and available safety and tolerability data from these studies support further clinical development of AEG33773. The current study is proposed as a proof-of-concept study to assess the potential analgesic efficacy of AEG33773 to reduce pain associated with chronic Diabetic Peripheral Neuropathy.

Condition or Disease	Intervention/Treatment	Phase
Diabetic Peripheral Neuropathy Chronic Pain	Drug: AEG33773 oral dosing	Phase 2

Detailed Description

Doses of AEG33773 selected for evaluation in this study provide a dose range (i.e., 100-400 mg) that may potentially include both a minimally effective dose and a maximum tolerated dose. Doses up to 400 mg were well tolerated in single- and multiple-dose Phase 1 studies.

Before initiation of treatment with study drug, other analgesic medications will be discontinued during a 7-day Washout Period, and neuropathic pain will be assessed (in the absence of analgesic medication) over the next 3 days (Pain Assessment Period). Pain intensity level during these 3 days will be recorded daily, and only those subjects who meet predefined pain intensity threshold criteria on all 3 days will be eligible to receive study drug. Because pain may increase after analgesic medications have been discontinued, the combined length of the Washout and Pain Assessment Periods is limited in order that subjects who experience increased pain during this time may begin treatment with study drug without undue delay. This design will allow for adequate Baseline pain assessment over 3 days while avoiding a more prolonged period of increasing pain in the absence of analgesic medications.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

128 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

Study Start Date :

Mar 1, 2009

Actual Primary Completion Date :

Dec 1, 2009

Actual Study Completion Date :

Feb 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo 4 Capsules of Placebo	Drug: AEG33773 oral dosing AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Active Comparator: 100 mg One 100 mg capsule and 3 placebo capsules of AEG33773	Drug: AEG33773 oral dosing AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Active Comparator: 200 mg Two 100 mg capsules and two placebo capsules	Drug: AEG33773 oral dosing AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Active Comparator: 400 mg Four 100 mg AEG33773 capsules	Drug: AEG33773 oral dosing AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days

Outcome Measures

Primary Outcome Measures

To evaluate the potential efficacy of AEG33773 in reducing chronic pain due to DPN [1 year]

Secondary Outcome Measures

To evaluate a range of AEG33773 doses that provide efficacy [1 year]
To determine a minimally effective dose of AEG33773 [1 year]
To determine a maximally tolerated dose of AEG33773 [1 year]
To evaluate the safety and tolerability of AEG33773 [1 year]
To explore AEG33773-dependent pharmacodynamic (PD) effects in blood of patients [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female age 18 to 75 years
Patients with type 1 or type 2 diabetes mellitus
DPN as determined by the investigator based on clinical history, clinical examination, and assessment of signs and symptoms
Stable diabetic control over the preceding 3 months, as determined by the investigator based on available medical information (e.g., hemoglobin A1c [HbA1c] and/or blood glucose levels)
HbA1c ≤ 12 % at the Screening visit
Pain persisting for more than 3 months and less than 5 years
Completion of 3 daily pain intensity reports (using the 11-point NPRS) over the 3 days immediately preceding the day of randomization
Pain intensity (NPRS) score of ≥ 5 for all 3 of the 3 days immediately preceding the day of randomization
Completed a washout (before first NPRS assessment) of at least 7 days for any of the following medications: α2-δ antagonists (e.g., gabapentin, pregabalin), opiate analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), topical lidocaine, anti-epileptic drugs, serotonin and norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine), tricyclic antidepressants prescribed for pain, skeletal muscle relaxants, orally administered steroids, capsaicin, mexiletene, centrally acting analgesics (dextromethorphan, tramadol), alpha lipoic acid, and any supplement or herbal product used to treat DPN symptoms
Women must be neither pregnant nor lactating. Women of childbearing age must have a confirmed negative pregnancy test and must practice medically acceptable methods of contraception throughout the trial and for at least 30 days after the last dose of study drug
Male subjects and/or their female partners must be using medically acceptable methods of contraception for the entire duration of the study, and for at least 90 days after the last study drug dose
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
A willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

Age younger than 18 years or older than 75 years
Are pregnant or breast feeding
Female patients of childbearing potential unwilling to use a medically acceptable form of contraception (i.e., hormonal birth control, intrauterine device [IUD], double barrier [male condom or female condom with a diaphragm], or a barrier method plus a spermicidal agent [contraceptive foam, jelly, or cream]) Female patients are considered to be of childbearing potential unless they have been postmenopausal for at least 1 year, are biologically sterile, or are surgically sterile (history of hysterectomy, bilateral oophorectomy, or bilateral tubal ligation.
Male patients (and/or their female partners) unwilling to use a medically acceptable form of contraception during participation in the study and for at least 90 days after the last dose of study drug. Medically acceptable forms of contraception are hormonal birth control, intrauterine device (IUD), double barrier (male condom or female condom with a diaphragm), or a barrier method plus a spermicidal agent (contraceptive foam, jelly, or cream)
Treatment with local anesthetic nerve blocks within the last 30 days before the Screening visit
Other severe pain which may impair the self-assessment of pain due to DPN
Participation in another study within 30 days before the Screening visit and/or during study participation
History of drug or alcohol abuse within the past 2 years
Creatinine clearance < 50 mL/min at the Screening visit
Malignancy other than basal cell carcinoma and carcinoma in situ within the past 2 years
History of chronic hepatitis B or C, hepatitis within the past 3 months before the Screening visit, or any history of human immunodeficiency virus (HIV) infection
Clinically significant hepatic, respiratory, hematological, cardiovascular, renal, or neurological disease, with the exception of diabetic peripheral neuropathy
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times higher than the upper limit of the laboratory normal reference range at the Screening visit
ECG with a QTcB > 470 ms at the Screening visit or at Baseline (if at either the Screening visit or Baseline the ECG shows a QTcB > 470 ms, then the investigator may immediately repeat the ECG twice and the QTcB value for inclusion/exclusion purposes will be determined by calculating the average of the 3 readings)
Immunocompromised state
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Neurological Research Institute	Santa Monica	California	United States	90404
2	Radiant Research	Cincinnatti	Ohio	United States	45249
3	Wells Institute for Health Awareness	Kettering	Ohio	United States	45429
4	Altoona Center for Clinical Research	Duncansville	Pennsylvania	United States	16635
5	UT Southwestern Medical Center	Dallas	Texas	United States	75390
6	Multiprofile Hospital for Active Treatment - Internal Department	Byala		Bulgaria	7100
7	University Multiprofile Hospital for Active Treatment - Clinic of Endocrinology and Metabolic Diseases	Pleven		Bulgaria	5800
8	University Multiprofile Hospital for Active Treatment - Clinic of Endocrinology and Metabolic Diseases	Plovdiv		Bulgaria	4002
9	Multiprofile Hospital for Active Treatment - Therapeutical and Endocrinology Department	Ruse		Bulgaria	7002
10	University Multiprofile Hospital Treatment Stara Zagora	Stara Zagora		Bulgaria	6003
11	Clinique d'Endocrinologie de l'Outaouais	Hull	Quebec	Canada	J8V 2P5
12	Centre de Recherche Clinique de Laval	Laval	Quebec	Canada	H7T 2P5
13	Hopital de l'Enfant Jesus	Quebec		Canada	G1J 1Z4
14	Medical Center "Dr. Negrisanu" SRL	Timisoara	Transylvania	Romania	300456
15	S.C. Nicodiab SRL	Bucharest		Romania	010496
16	National Clinical Institute of Diabetes, Nutrition and Metabolic Diseases	Bucharest		Romania	020045
17	National Institute of Diabetes Nutrition and Metabolic Diseases	Bucharest		Romania	020475
18	Mosilor Diabetes Mellitus and Obesity Medical	Bucharest		Romania	020859
19	Emergency Clinical County Hospital Cluj County	Cluj Napoca		Romania	4000006
20	St. Spiridon Emergency Clinical County Hospital	Iasi		Romania	700111